Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Generic User Fee Renewal Talks Faced 'Buyer's Remorse' From GDUFA I

27 Oct 2016

• By Sue Sutter

PS1610_Failed Executive_1200x675

Related Content

Generic Drug First-Cycle Approval Rates Lagging Under GDUFA I

26 Oct 2016

ANDA Approvals, Complete Responses Hit Record In FY 2016

12 Oct 2016

GDUFA II: Industry Shares Stage With FDA

23 Oct 2016

GDUFA II? Mylan Lawyer Questions User Fee Law’s Future Absent FDA Progress

27 Apr 2015

GPhA Warns FDA On ANDA Review Transparency

13 Aug 2015

GDUFA II Negotiations: Contract Manufacturers Gain Seat At Table

06 Jul 2015

ANDAs Can Get Priority, Eight-Month Reviews Under User Fee Deal

24 Sep 2016

Complex ANDAs To Be Allowed Pre-Submission Product Meetings

24 Oct 2016

Related Companies

Teva Pharmaceutical Industries Ltd.

Fresenius SE & Co. KGaA

Additional Topics

Policy Generic Drugs Drug Review BioPharmaceutical

More from Generics

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.